In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

In 2021, Kentucky reported the highest cancer incidence rate in the United States, with around 510 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2021.

In 2021, there were around 158 new cases of breast cancer per 100,000 population in the state of Connecticut, making it the state with the highest breast cancer incidence rate that year. This statistic shows the incidence rate of breast cancer in the U.S. in 2021, by state.

In 2016 in India during the measured time period, Kerala had the highest crude incidence rate of cancer at 135.3 incidences for every 100,000 inhabitants. Mizoram in East India followed with almost 122 incidences during the same time period.

Cancer was responsible for around 142 deaths per 100,000 population in the United States in 2022. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated 65,790 deaths among men alone in 2024. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as 99 percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around 81 percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. A recent poll indicated that many U.S. adults believed smoking cigarettes and using other tobacco products increased a person’s risk of developing cancer, but a much smaller percentage believed the same for proven risk factors such as obesity and drinking alcohol.

This map shows the incidence rate per 100,000 for all cancer types by county. Counties are shaded based on quartile distribution. The lighter shaded counties have lower cancer incidence rates. The darker shaded counties have higher cancer incidence rates. New York State Community Health Indicator Reports (CHIRS) were developed in 2012, and are updated annually to consolidate and improve data linkages for the health indicators included in the County Health Assessment Indicators (CHAI) for all communities in New York. The CHIRS present data for more than 300 health indicators that are organized by 15 different health topics. Data if provided for all 62 New York State counties, 11 regions (including New York City), the State excluding New York City, and New York State. For more information, check out: http://www.health.ny.gov/statistics/chac/indicators/. The "About" tab contains additional details concerning this dataset.

In 2021, Utah had the highest rate of skin cancer, with an estimated 46 people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

This map shows the incidence rate per 100,000 of lung and bronchus cancer by county. Counties are shaded based on quartile distribution. The lighter shaded counties have lower incidence rates of lung and bronchus cancer. The darker shaded counties have higher incidence rates of lung and bronchus cancer. New York State Community Health Indicator Reports (CHIRS) were developed in 2012, and are updated annually to consolidate and improve data linkages for the health indicators included in the County Health Assessment Indicators (CHAI) for all communities in New York. The CHIRS present data for more than 300 health indicators that are organized by 15 different health topics. Data if provided for all 62 New York State counties, 8 regions (including New York City), the State excluding New York City, and New York State. For more information, check out: http://www.health.ny.gov/statistics/chac/indicators/. The "About" tab contains additional details concerning this dataset.

In 2022, there were 14 deaths from breast cancer per 100,000 population in the state of Massachusetts, the lowest of any state that year. This statistic shows the death rate from breast cancer in the U.S. in 2022, by state.

In 2021, there were 150 cases of prostate cancer per 100,000 population in the state of Connecticut, making it the state with the highest prostate cancer incidence rate that year. This statistic shows the incidence rate of prostate cancer in the U.S. in 2021, by state.

MMWR Surveillance Summary 66 (No. SS-1):1-8 found that nonmetropolitan areas have significant numbers of potentially excess deaths from the five leading causes of death. These figures accompany this report by presenting information on potentially excess deaths in nonmetropolitan and metropolitan areas at the state level. They also add additional years of data and options for selecting different age ranges and benchmarks. Potentially excess deaths are defined in MMWR Surveillance Summary 66(No. SS-1):1-8 as deaths that exceed the numbers that would be expected if the death rates of states with the lowest rates (benchmarks) occurred across all states. They are calculated by subtracting expected deaths for specific benchmarks from observed deaths. Not all potentially excess deaths can be prevented; some areas might have characteristics that predispose them to higher rates of death. However, many potentially excess deaths might represent deaths that could be prevented through improved public health programs that support healthier behaviors and neighborhoods or better access to health care services. Mortality data for U.S. residents come from the National Vital Statistics System. Estimates based on fewer than 10 observed deaths are not shown and shaded yellow on the map. Underlying cause of death is based on the International Classification of Diseases, 10th Revision (ICD-10) Heart disease (I00-I09, I11, I13, and I20–I51) Cancer (C00–C97) Unintentional injury (V01–X59 and Y85–Y86) Chronic lower respiratory disease (J40–J47) Stroke (I60–I69) Locality (nonmetropolitan vs. metropolitan) is based on the Office of Management and Budget’s 2013 county-based classification scheme. Benchmarks are based on the three states with the lowest age and cause-specific mortality rates. Potentially excess deaths for each state are calculated by subtracting deaths at the benchmark rates (expected deaths) from observed deaths. Users can explore three benchmarks: “2010 Fixed” is a fixed benchmark based on the best performing States in 2010. “2005 Fixed” is a fixed benchmark based on the best performing States in 2005. “Floating” is based on the best performing States in each year so change from year to year. SOURCES CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov). REFERENCES Moy E, Garcia MC, Bastian B, Rossen LM, Ingram DD, Faul M, Massetti GM, Thomas CC, Hong Y, Yoon PW, Iademarco MF. Leading Causes of Death in Nonmetropolitan and Metropolitan Areas – United States, 1999-2014. MMWR Surveillance Summary 2017; 66(No. SS-1):1-8. Garcia MC, Faul M, Massetti G, Thomas CC, Hong Y, Bauer UE, Iademarco MF. Reducing Potentially Excess Deaths from the Five Leading Causes of Death in the Rural United States. MMWR Surveillance Summary 2017; 66(No. SS-2):1–7.

ObjectiveThis study aimed to assess the cost-effectiveness of lung cancer screening (LCS) employing volume-based low-dose computed tomography (LDCT) in contrast to the absence of screening, targeting an asymptomatic high-risk population in Greece, leveraging the outcomes derived from the NELSON study, the largest European randomized control trial dedicated to LCS.MethodsA validated model incorporating a decision tree and an integrated state-transition Markov model was used to simulate the identification, diagnosis, and treatments for a population at high risk of developing lung cancer, from a healthcare payer perspective. Screen-detected lung cancers, costs, life years (LYs), quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) were predicted. Sensitivity and scenario analyses were conducted to assess the robustness and reliability of the model’s outcomes under varying parameters and hypothetical situations.ResultsAnnual LCS with volume-based LDCT detected 17,104 more lung cancer patients at early-stage among 207,885 screening population, leading to 8,761 premature lung cancer deaths averted. In addition, in contrast to no screening, LCS yielded 86,207 LYs gained and 50,207 incremental QALYs at an additional cost of €278,971,940, resulting in an ICER of €3,236 per LY and €5,505 per QALY, over a lifetime horizon. These estimates were robust in sensitivity analyses.ConclusionsLCS with volume-based LDCT, targeting an asymptomatic high-risk population, is highly cost-effective in Greece. Implementing LCS ensures efficient allocation of public healthcare resources while delivering substantial clinical benefits to lung cancer patients.

This map uses age-standardized ratios to further aid in regional comparisons. A value of 1.0 would indicate that the region rate is identical to the overall Canadian rate; a value greater than 1.0 would indicate that the rate for that region is higher than the Canadian rate; and, in turn, a ratio value less than 1.0 would indicate that the rate for the specific region is lower than the Canadian rate. Statistically low incidences of breast cancer are found in Newfoundland and Labrador, the territories, and northern areas of most provinces. Otherwise, each province has one or more pockets of significantly high breast cancer incidence. Health status refers to the state of health of a person or group, and measures causes of sickness and death. It can also include people’s assessment of their own health.

Characteristics of 12,413 colorectal cancer cases from 2003–2013 in Nevada.

According to cognitive market research, the global lung cancer therapeutics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

The lungs are two spongy organs in the chest that control breathing. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer. The risk of lung cancer increases with the length of time and number of cigarettes smoked.
The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals
The chemotherapy segment dominated the lung cancer therapeutics market revenue in 2024 and is projected to be the fastest-growing segment during the forecast period. Chemotherapy goes throughout the entire body for tumor cells, whereas radiation and surgery target a single region of the body.
Moreover, this market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines.
There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the instruments adds up to the total cost.

Market Dynamics of the Lung Cancer Therapeutics

Key Drivers of the Lung Cancer Therapeutics

The strong prevalence of lung cancer is notably driving market growth.

One of the most prevalent forms of cancer is lung cancer. Several reasons, including the aging population and lifestyle changes, have contributed to a notable increase in the number of new instances of cancer, particularly lung cancer, in recent years. In the United States, 6.2% of the population is at risk of developing lung cancer. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals. • For instance, according to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of color at 20%. Hence, the increasing prevalence of cancer and the need for effective treatment is likely to contribute to market growth. (Source:https://www.lung.org/research/state-of-lung-cancer/key-findings)

Rising pollution due to rapid industrialization increases the incidences of lung cancer

Air pollution (outdoor and indoor particulate matter and ozone) is closely linked to the rising prevalence of heart disease and strokes, lung cancer, lower respiratory infections, diabetes, and chronic obstructive pulmonary disease (COPD). The Global Burden of Disease Study Report (2019) ranks air pollution as the third leading cause of death worldwide. Globally, air pollution is responsible for 6.82 million deaths annually, of which 33% are caused by interior pollution and 66% by outdoor pollution. • For instance, According to the conference organized by the Associated Chambers of Commerce and Industry of India (ASSOCHAM), ‘Lung Cancer- Awareness, Prevention, Challenges & Treatment’, air pollution is the leading cause of the rise of lung cancer in the country. Around 63 out of the 100 most polluted places on earth belong to India. (Source:https://www.assocham.org/press-release-page.php?release-name=air-pollution-is-the-major-cause-of-lung-cancer-in-india-say-health-experts)

Restraints of the Lung Cancer Therapeutics

Regional disparities in treatment will hamper the market for lung cancer therapeutics

Lung cancer is the most prevalent cause of cancer-related deaths globally, and its impact is particularly felt in lower- and middle-income countries (LMICs), where access to early and effective diagnosis and treatment is often restricted. WHO data show that whereas 90% of cancer patients in high-income countries have access to therapy, only roughly 30% of cancer patients in low-income countries do. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the i...

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. This study was designed to compare the cost-effectiveness of these three novel therapies in this patient population.Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. Health states included progression-free survival, progressive disease, end-stage disease, and death. Clinical efficacy and safety data were derived from phase III clinical trials and health state utilities and costs data were collected from published resources. Two scenario analyses were conducted to assess the impact of varying subsequent anticancer therapies on the cost-effectiveness of these 3 ICIs and cost-effectiveness of pembrolizumab combined with chemotherapy versus these 3 first-line ICI monotherapies.Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. The first scenario analysis yielded similar results as our base case analysis. The second scenario analysis founded the ICERs for pembrolizumab plus chemotherapy were $393,359/QALY, $190,994/QALY and $33,230/QALY, respectively, compared with cemiplimab, pembrolizumab and atezolizumab.Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. Our scenario analysis results supported the cemiplimab plus chemotherapy as a second-line therapy and suggested an extended QALY but overwhelming cost linking to pembrolizumab plus chemotherapy.

This dataset presents the footprint of participation statistics in the National Bowel Cancer Screening Program (NBCSP) for people aged 50 to 74. The NBCSP began in 2006. It aims to reduce morbidity …Show full descriptionThis dataset presents the footprint of participation statistics in the National Bowel Cancer Screening Program (NBCSP) for people aged 50 to 74. The NBCSP began in 2006. It aims to reduce morbidity and mortality from bowel cancer by actively recruiting and screening the eligible target population for early detection or prevention of the disease. The data spans the years of 2015-2017 and is aggregated to Statistical Area Level 2 (SA2) geographic areas from the 2011 Australian Statistical Geography Standard (ASGS). Cancer is one of the leading causes of illness and death in Australia. Cancer screening programs aim to reduce the impact of selected cancers by facilitating early detection, intervention and treatment. Australia has three cancer screening programs: BreastScreen Australia National Cervical Screening Program (NCSP) National Bowel Cancer Screening Program (NBCSP) The National cancer screening programs participation data presents the latest cancer screening participation rates and trends for Australia's 3 national cancer screening programs. The data has been sourced from the Australian Institute of Health and Welfare (AIHW) analysis of National Bowel Cancer Screening Program register data, state and territory BreastScreen Australia register data and state and territory cervical screening register data. For further information about this dataset, visit the data source:Australian Institute of Health and Welfare - National Cancer Screening Programs Participation Data Tables. Please note: AURIN has spatially enabled the original data. Participation rates represent the percentage of people invited to screen through the NBCSP during the relevant 2-year period, who returned a completed screening test within that period or by 30 June of the following year. The number of individuals invited to screen excludes those who deferred or opted out without completing their screening test. Values assigned to n.p. in the original data have been set to null. SA2 areas were assigned to NBCSP invitees using an SA1 to SA2 correspondence. Those invitees without reliable SA1 details were mapped with a postcode to SA2 correspondences instead, which may lead to some minor inaccuracies in results. Some invitee SA1 codes and postcodes cannot be attributed to an SA2. These invitees were included in an 'Unknown' group where applicable. Some postcodes cross SA2 boundaries, leading to slight inaccuracies. Biennial screening for those aged 50-74 is not fully rolled out. During the time period reported, the specific ages invited within the 50-74 age range included 50, 54, 55, 58, 60, 64, 65, 68, 70, 72 and 74. These results calculate participation rates using the new NBCSP performance indicator specifications. This indicator now measures a 2-year invitation period and also excludes those who opted off or suspended participation. Therefore, these results cannot be compared to rates reported prior to 2014. NBCSP participation rates per area are not related to bowel cancer incidence rates. SA2 areas with a numerator less than 20 or a denominator less than 100 have been suppressed. SA2 data for the Blue Mountains - South, Christmas Island, Cocos (Keeling) Islands, Illawarra Catchment Reserve, Jervis Bay and Lord Howe Island were suppressed due to reliability concerns from low numbers in these regions. The 2015-2016 period covers 1 January 2015 to 31 December 2016, and the 2016-2017 period covers 1 January 2016 to 31 December 2017. Participation by SA2 is not available for the period 2014-2015. The number of people in different SA2s may not sum to 'Australia' total due to rounding.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around a third never used sunscreen.

In 2022, the incidence of lung cancer among men in Europe was highest in Hungary at 138.4 per 100,000, while Sweden had the lowest incidence. The incidence of lung cancer recorded among women in Denmark was over 79 per 100,000 population. Across the European Union overall, the rate of lung cancer diagnoses was 94.5 per 100,000 among men and 44.1 per 100,000 among women. Smoking and lung cancer risk The connection between smoking and the increased risk of health problems is well established. As of 2021, Hungary had one of the highest daily smoking rates in Europe, with over a quarter of adults smoking daily in the Central European country. The only other countries with a higher share of smoking adults were Bulgaria and Turkey. A positive development though, is the share of adults smoking every day has decreased in almost every European country since 2011. The rise of vaping Originally marketed as a device to help smokers quit, e-cigarettes or vapes have seen increased popularity among people who never smoked cigarettes, especially young people. The use of vapes among young people was reported to be highest in Estonia, Czechia, and Ireland. The dangers of vaping have not been examined over the long term. In the EU there have been attempts to make ‘vapes’ less accessible and appealing for young people, which would include such things as banning flavors and stopping the sale of disposable e-cigarettes.